Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations-MedSci.cn

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

Tausch, E; Ljungstrom, V; Agathangelidis, A; Zapatka, M; Scarfo, L; Jebaraj, BMC; Yosifov, DY; Muller, A; Munugalavadla, V; Degenhardt, JD; Ghia, P; Rosenquist, R; Stilgenbauer, S

Stilgenbauer, S (通讯作者)，Ulm Univ, Div Chron Lymphocyt Leukemia, Dept Internal Med 3, Albert Einstein Allee 23, D-89081 Ulm, Germany.

BLOOD, 2022; 139 (22): 3340

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

科室

工具

服务